Next Article in Journal
Marine Collagen Peptides from the Skin of Nile Tilapia (Oreochromis niloticus): Characterization and Wound Healing Evaluation
Next Article in Special Issue
Laucysteinamide A, a Hybrid PKS/NRPS Metabolite from a Saipan Cyanobacterium, cf. Caldora penicillata
Previous Article in Journal / Special Issue
Another Look at Pyrroloiminoquinone Alkaloids—Perspectives on Their Therapeutic Potential from Known Structures and Semisynthetic Analogues
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessFeature PaperReview
Mar. Drugs 2017, 15(4), 99; doi:10.3390/md15040099

Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates

1
Wayne, PA 19087, USA
2
Gaithersburg, MD 20877, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Keith B. Glaser
Received: 28 February 2017 / Revised: 24 March 2017 / Accepted: 27 March 2017 / Published: 29 March 2017
(This article belongs to the Special Issue Marine Drugs as Antitumour Agents 2017)
View Full-Text   |   Download PDF [1134 KB, uploaded 29 March 2017]   |  

Abstract

In this review, we have attempted to describe all of the antibody–drug conjugates using a marine-derived compound as the “warhead”, that are currently in clinical trials as listed in the current version of the NIH clinical trials database (clinicaltrials.gov). In searching this database, we used the beta-test version currently available, as it permitted more specific search parameters, since the regular version did not always find trials that had been completed in the past with some agents. We also added small discussion sections on candidates that are still at the preclinical stage, including a derivative of diazonamide that has an unusual interaction with tubulin (DZ-23840), which may also be a potential warhead in the future. View Full-Text
Keywords: Antibody Drug Conjugates (ADCs); marine derived antitumor agents; clinical trials Antibody Drug Conjugates (ADCs); marine derived antitumor agents; clinical trials
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Newman, D.J.; Cragg, G.M. Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates. Mar. Drugs 2017, 15, 99.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top